Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ACOR

Acorda Therapeutics, Inc.

Apr 11 • 04:00PM ET

0.6610

Dollar change 0.0000
Percentage change 0.00	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-203.57	Insider Own	0.69%	Shs Outstand	1.24M	Perf Week	-60.65%
Market Cap	0.82M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.22M	Perf Month	-94.78%
Income	-	PEG	-	EPS next Q	-	Inst Own	13.22%	Short Float	0.67%	Perf Quarter	-95.35%
Sales	117.63M	P/S	0.01	EPS this Y	-	Inst Trans	-	Short Ratio	0.06	Perf Half Y	-93.76%
Book/sh	-127.17	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.01M	Perf Year	-93.59%
Cash/sh	-	P/C	-	EPS next 5Y	46.00%	ROE	-	52W Range	0.61 - 24.20	Perf YTD	-95.62%
Dividend Est.	-	P/FCF	-	EPS past 5Y	16.45%	ROI	-	52W High	-97.27%	Beta	1.71
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	8.08%	ATR (14)	1.07
Dividend Ex-Date	-	Current Ratio	-	EPS Y/Y TTM	-187.99%	Oper. Margin	-	RSI (14)	16.93	Volatility	25.33% 18.93%
Employees	102	Debt/Eq	-	Sales Y/Y TTM	-0.79%	Profit Margin	-	Recom	2.00	Target Price	-
Option/Short	No / No	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.00	Prev Close	0.66
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	20.70%	Earnings	Apr 01 AMC	Avg Volume	132.57K	Price	0.66
SMA20	-91.89%	SMA50	-94.40%	SMA200	-94.95%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-21	Upgrade	H.C. Wainwright	Neutral → Buy	$5 → $10
Aug-14-19	Downgrade	H.C. Wainwright	Buy → Neutral	$31 → $6
May-23-19	Initiated	Wedbush	Neutral
Dec-11-18	Downgrade	Goldman	Neutral → Sell
Aug-07-18	Reiterated	Stifel	Hold	$15 → $25
Feb-16-18	Upgrade	Piper Jaffray	Neutral → Overweight
Jan-17-18	Reiterated	H.C. Wainwright	Buy	$34 → $31
Nov-28-17	Resumed	Piper Jaffray	Neutral	$22
Nov-16-17	Downgrade	Stifel	Buy → Hold	$26 → $15
Nov-16-17	Downgrade	Raymond James	Mkt Perform → Underperform
Nov-09-17	Initiated	Oppenheimer	Perform
Nov-08-17	Initiated	H.C. Wainwright	Buy	$35
Oct-06-17	Resumed	Goldman	Sell	$20
Jul-11-17	Initiated	Jefferies	Hold
Apr-03-17	Downgrade	JP Morgan	Overweight → Neutral
Feb-15-17	Upgrade	Goldman	Sell → Neutral
Nov-30-16	Upgrade	JP Morgan	Neutral → Overweight
Oct-04-16	Resumed	Leerink Partners	Mkt Perform	$25
Mar-30-16	Initiated	Goldman	Sell
Sep-01-15	Initiated	Raymond James	Mkt Perform

Show Previous Ratings

Apr-06-24 03:00PM	Riskiest Junk Bonds Shunned in Europe on Rising Risk of Default (Bloomberg)
Apr-03-24 05:30PM	Acorda Therapeutics Announces Nasdaq Delisting Notification (Business Wire) -20.40%
Apr-02-24 08:57AM	Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today? (InvestorPlace) -81.44%
08:05AM	Acorda files for bankruptcy, reveals asset sale plan (BioPharma Dive)
Apr-01-24 06:35PM	Acorda Therapeutics and Merz Announce Signing of Stalking Horse Asset Purchase Agreement (Business Wire)
04:01PM	Loading…
04:01PM	Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024 (Business Wire)
Mar-25-24 04:01PM	Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024 (Business Wire)
Jan-11-24 08:01AM	Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA by January 2025 (Business Wire)
Nov-14-23 10:34AM	Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 04:07PM	Acorda: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Acorda Therapeutics Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-06-23 04:01PM	Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023 (Business Wire)
08:00AM	Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA (Business Wire)
Aug-28-23 12:42PM	Acorda Therapeutics (ACOR): A Comprehensive Analysis of Its Market Value (GuruFocus.com) -10.09%
Aug-08-23 04:21PM	Acorda: Q2 Earnings Snapshot (Associated Press Finance) -6.25%
04:01PM	Loading…
04:01PM	Acorda Therapeutics Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-02-23 08:00AM	Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: "For The Fighters" (Business Wire)
Aug-01-23 08:00AM	Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023 (Business Wire)
Jun-28-23 05:08PM	Tom Burns Elected to the Acorda Therapeutics Board of Directors (Business Wire) +5.71%
Jun-26-23 08:23AM	Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (Business Wire)
Jun-05-23 09:06AM	Little Excitement Around Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Revenues (Simply Wall St.)
Jun-02-23 04:01PM	Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split (Business Wire) -9.35%
May-31-23 04:01PM	Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split (Business Wire)
May-30-23 08:00AM	Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A (Business Wire)
May-12-23 05:28AM	Q1 2023 Acorda Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -17.25%
May-11-23 04:29PM	Acorda: Q1 Earnings Snapshot (AP Finance)
04:01PM	Acorda Therapeutics Reports First Quarter 2023 Financial Results (Business Wire)
02:26PM	3 Penny Stocks to Avoid as Interest Rates Rise in 2023 (InvestorPlace)
May-10-23 07:00AM	Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash (Business Wire)
May-08-23 07:00AM	Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China (Business Wire) +77.78%
09:41AM	Loading…
May-04-23 09:41AM	Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023 (Business Wire)
Apr-24-23 08:00AM	Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting (Business Wire)
Apr-03-23 08:00AM	Acorda Launches INBRIJA® TV Commercial for Parkinsons Awareness Month (Business Wire)
Mar-27-23 08:00AM	Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A (Business Wire)
Mar-09-23 07:00AM	Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire) -18.73%
Mar-07-23 07:00AM	ESTEVE Launches INBRIJA® in Spain (Business Wire)
Mar-06-23 03:43PM	Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023 (Business Wire)
Feb-14-23 04:46PM	Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement (Business Wire)
Jan-31-23 04:01PM	Acorda Therapeutics to Present at Sequire Biotechnology Conference (Business Wire) +6.42%
Jan-05-23 04:20PM	Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA® (Business Wire) -10.89%
Dec-22-22 08:00AM	Acorda Therapeutics Announces Revised Long-Term Financial Guidance (Business Wire)
Dec-20-22 05:30PM	Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing (Business Wire)
Dec-05-22 07:01AM	Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash (Business Wire)
Nov-19-22 08:12AM	Acorda Therapeutics Third Quarter 2022 Earnings: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021) (Simply Wall St.)
Nov-11-22 09:52AM	Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders (Business Wire) +12.44%
Nov-04-22 09:25AM	Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders (Business Wire)
Nov-01-22 04:01PM	Acorda Therapeutics Reports Third Quarter 2022 Financial Results (Business Wire) -25.22%
Oct-27-22 07:00AM	Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance (Business Wire) +21.72%
Oct-25-22 04:01PM	Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022 (Business Wire)
Oct-21-22 07:00AM	Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D. (Business Wire)
Oct-19-22 07:00AM	ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split (Business Wire) -20.27%
Oct-18-22 07:00AM	Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt (Business Wire) -18.62%
Oct-16-22 04:48PM	Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case (Business Wire)
Oct-10-22 06:30AM	Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders (Business Wire)
Sep-08-22 04:01PM	Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (Business Wire) +6.38%
Aug-29-22 07:00AM	Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals (Business Wire)
Aug-19-22 08:00AM	Acorda Therapeutics Announces Resignation of Chief Operating Officer (Business Wire)
Aug-04-22 04:01PM	Acorda Therapeutics Reports Second Quarter 2022 Financial Results (Business Wire) +12.69%
Jul-28-22 04:01PM	Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022 (Business Wire)
Jun-16-22 09:31AM	Why Acorda Therapeutics Shares Gaining Today? (Benzinga) +54.47%
07:01AM	Esteve Launches INBRIJA® in Germany (Business Wire)
May-11-22 04:01PM	Acorda Therapeutics Reports First Quarter 2022 Financial Results (Business Wire) -10.27%
04:01PM	Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America (Business Wire)
May-04-22 04:01PM	Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022 (Business Wire) -5.34%
Mar-09-22 04:01PM	Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire)
Feb-24-22 05:00PM	Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022 (Business Wire)
Jan-04-22 07:11AM	Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (Business Wire)
Jan-03-22 04:01PM	John Varian Joins Acorda Therapeutics Board of Directors (Business Wire)
Nov-09-21 04:01PM	Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team (Business Wire)
04:01PM	Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany (Business Wire)
Nov-02-21 07:00AM	Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021 (Business Wire)
Sep-09-21 08:01AM	Acorda Therapeutics Announces Corporate Restructuring, Management Changes (Business Wire)
Aug-05-21 05:45PM	Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.33%
04:01PM	Acorda Therapeutics Reports Second Quarter 2021 Financial Results (Business Wire)
Jul-30-21 04:01PM	Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021 (Business Wire) -5.06%
Jul-27-21 03:02PM	Will Acorda Therapeutics (ACOR) Report Negative Q2 Earnings? What You Should Know (Zacks) -7.69%
Jul-23-21 07:28AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +24.15%
Jul-22-21 04:01PM	Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain (Business Wire)
Jun-18-21 10:46PM	Hedge Funds Are Buying Acorda Therapeutics Inc (ACOR) Again (Insider Monkey) -8.04%
Jun-16-21 07:00AM	Acorda Therapeutics Announces Repayment of Convertible Senior Notes (Business Wire)
May-06-21 05:15PM	Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Acorda Therapeutics Reports First Quarter 2021 Financial Results (Business Wire)
Apr-29-21 04:30PM	Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021 (Business Wire)
Apr-27-21 12:00PM	All You Need to Know About Acorda (ACOR) Rating Upgrade to Strong Buy (Zacks)
Apr-20-21 09:46AM	J&J (JNJ) Q1 Earnings Top, COVID-19 Vaccine Brings $100M Sales (Zacks)
Apr-12-21 07:00AM	Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of "A Taste for Life with Zarela" (Business Wire)
Apr-01-21 07:51AM	QIAGEN's (QGEN) NeuMoDx Multiplex Test Receives FDA EUA (Zacks)
Mar-12-21 10:01AM	Tandem (TNDM) Grows on Abbott, Dexcom Pacts Amid COVID-19 Woes (Zacks)
Mar-11-21 08:52AM	Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins (Zacks) +5.01%
Mar-10-21 11:30AM	Has Acorda Therapeutics (ACOR) Outpaced Other Medical Stocks This Year? (Zacks)
Mar-08-21 11:12PM	The Acorda Therapeutics, Inc. (NASDAQ:ACOR) Analyst Just Boosted Their Forecasts By A Dazzling Amount (Simply Wall St.)
05:44PM	Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference (Business Wire)
Mar-05-21 08:15AM	The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study (Benzinga) -23.01%
Mar-04-21 05:45PM	Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +7.79%
04:01PM	Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results (Business Wire)
Mar-03-21 12:52PM	Encompass Health (EHC) Ties Up for Better Homehealth Care (Zacks)
Mar-02-21 08:43AM	Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates (Zacks)
Feb-26-21 10:10AM	Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall (Zacks)
Feb-25-21 07:00AM	Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021 (Business Wire)
Feb-19-21 07:00AM	Acorda Therapeutics Announces Departure of Chief, Business Operations (Business Wire)

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACOR

Acorda Therapeutics, Inc.

Upgrade your FINVIZ experience